Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Batrachochytrium dendrobatidis and the Decline and Survival of the Relict Leopard Frog.

Jaeger JR, Waddle AW, Rivera R, Harrison DT, Ellison S, Forrest MJ, Vredenburg VT, van Breukelen F.

Ecohealth. 2017 Jun;14(2):285-295. doi: 10.1007/s10393-017-1240-2. Epub 2017 Apr 24.

PMID:
28439781
2.

Chronic Inhibition of Renal Outer Medullary Potassium Channel Not Only Prevented but Also Reversed Development of Hypertension and End-Organ Damage in Dahl Salt-Sensitive Rats.

Zhou X, Forrest MJ, Sharif-Rodriguez W, Forrest G, Szeto D, Urosevic-Price O, Zhu Y, Stevenson AS, Zhou Y, Stribling S, Dajee M, Walsh SP, Pasternak A, Sullivan KA.

Hypertension. 2017 Feb;69(2):332-338. doi: 10.1161/HYPERTENSIONAHA.116.08358. Epub 2016 Dec 5.

PMID:
27920129
3.

Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats.

Zhou X, Huang CH, Lao J, Pocai A, Forrest G, Price O, Roy S, Kelley DE, Sullivan KA, Forrest MJ.

Cardiovasc Diabetol. 2015 Mar 7;14:29. doi: 10.1186/s12933-015-0194-3.

4.
5.

Nothing a hot bath won't cure: infection rates of amphibian chytrid fungus correlate negatively with water temperature under natural field settings.

Forrest MJ, Schlaepfer MA.

PLoS One. 2011;6(12):e28444. doi: 10.1371/journal.pone.0028444. Epub 2011 Dec 21.

6.

Chronic antagonism of the mineralocorticoid receptor ameliorates hypertension and end organ damage in a rodent model of salt-sensitive hypertension.

Zhou X, Crook MF, Sharif-Rodriguez W, Zhu Y, Ruben Z, Pan Y, Urosevic-Price O, Wang L, Flattery AM, Forrest G, Szeto D, Zhao H, Roy S, Forrest MJ.

Clin Exp Hypertens. 2011;33(8):538-47. doi: 10.3109/10641963.2011.566956. Epub 2011 Sep 27.

7.

A potent and selective indole N-type calcium channel (Ca(v)2.2) blocker for the treatment of pain.

Tyagarajan S, Chakravarty PK, Park M, Zhou B, Herrington JB, Ratliff K, Bugianesi RM, Williams B, Haedo RJ, Swensen AM, Warren VA, Smith M, Garcia M, Kaczorowski GJ, McManus OB, Lyons KA, Li X, Madeira M, Karanam B, Green M, Forrest MJ, Abbadie C, McGowan E, Mistry S, Jochnowitz N, Duffy JL.

Bioorg Med Chem Lett. 2011 Jan 15;21(2):869-73. doi: 10.1016/j.bmcl.2010.11.067. Epub 2010 Nov 21.

PMID:
21195616
8.

Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate.

Shen HC, Ding FX, Raghavan S, Deng Q, Luell S, Forrest MJ, Carballo-Jane E, Wilsie LC, Krsmanovic ML, Taggart AK, Wu KK, Wu TJ, Cheng K, Ren N, Cai TQ, Chen Q, Wang J, Wolff MS, Tong X, Holt TG, Waters MG, Hammond ML, Tata JR, Colletti SL.

J Med Chem. 2010 Mar 25;53(6):2666-70. doi: 10.1021/jm100022r.

PMID:
20184326
9.

Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist.

Wisniewski T, Bayne E, Flanagan J, Shao Q, Wnek R, Matheravidathu S, Fischer P, Forrest MJ, Peterson L, Song X, Yang L, Demartino JA, Struthers M.

J Immunol Methods. 2010 Jan 31;352(1-2):101-10. doi: 10.1016/j.jim.2009.10.010. Epub 2009 Nov 10.

PMID:
19913021
10.

A novel 3-dimensional micro-ultrasound approach to automated measurement of carotid arterial plaque volume as a biomarker for experimental atherosclerosis.

Walker M 3rd, Campbell BR, Azer K, Tong C, Fang K, Cook JJ, Forrest MJ, Kempadoo K, Wright SD, Saltzman JS, MacIntyre E, Hargreaves R.

Atherosclerosis. 2009 May;204(1):55-65. doi: 10.1016/j.atherosclerosis.2008.09.013. Epub 2008 Sep 19.

PMID:
19135672
11.

Discovery of betamethasone 17alpha-carbamates as dissociated glucocorticoid receptor modulators in the rat.

Ali A, Balkovec JM, Greenlee M, Hammond ML, Rouen G, Taylor G, Einstein M, Ge L, Harris G, Kelly TM, Mazur P, Pandit S, Santoro J, Sitlani A, Wang C, Williamson J, Forrest MJ, Carballo-Jane E, Luell S, Lowitz K, Visco D.

Bioorg Med Chem. 2008 Aug 15;16(16):7535-42. doi: 10.1016/j.bmc.2008.07.037. Epub 2008 Jul 20.

PMID:
18691892
12.

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.

Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, Hershey JC, Keller WJ, Ma X, McPherson HE, Messina E, Peterson LB, Sharif-Rodriguez W, Siegl PK, Sinclair PJ, Sparrow CP, Stevenson AS, Sun SY, Tsai C, Vargas H, Walker M 3rd, West SH, White V, Woltmann RF.

Br J Pharmacol. 2008 Aug;154(7):1465-73. doi: 10.1038/bjp.2008.229. Epub 2008 Jun 9.

13.

Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor.

Shen HC, Ding FX, Luell S, Forrest MJ, Carballo-Jane E, Wu KK, Wu TJ, Cheng K, Wilsie LC, Krsmanovic ML, Taggart AK, Ren N, Cai TQ, Deng Q, Chen Q, Wang J, Wolff MS, Tong X, Holt TG, Waters MG, Hammond ML, Tata JR, Colletti SL.

J Med Chem. 2007 Dec 13;50(25):6303-6. Epub 2007 Nov 10.

PMID:
17994679
14.

Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists.

Carballo-Jane E, Gerckens LS, Luell S, Parlapiano AS, Wolff M, Colletti SL, Tata JR, Taggart AK, Waters MG, Richman JG, McCann ME, Forrest MJ.

J Pharmacol Toxicol Methods. 2007 Nov-Dec;56(3):308-16. Epub 2007 Jun 23.

PMID:
17643322
15.

Potential role for epidermal Langerhans cells in nicotinic acid-induced vasodilatation in the mouse.

Carballo-Jane E, Ciecko T, Luell S, Woods JW, Zycband EI, Waters MG, Forrest MJ.

Inflamm Res. 2007 Jun;56(6):254-61.

PMID:
17607550
16.

Novel glucocorticoids containing a 6,5-bicyclic core fused to a pyrazole ring: synthesis, in vitro profile, molecular modeling studies, and in vivo experiments.

Thompson CF, Quraishi N, Ali A, Mosley RT, Tata JR, Hammond ML, Balkovec JM, Einstein M, Ge L, Harris G, Kelly TM, Mazur P, Pandit S, Santoro J, Sitlani A, Wang C, Williamson J, Miller DK, Yamin TT, Thompson CM, O'Neill EA, Zaller D, Forrest MJ, Carballo-Jane E, Luell S.

Bioorg Med Chem Lett. 2007 Jun 15;17(12):3354-61. Epub 2007 Apr 5.

PMID:
17467988
17.

Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes.

Singer II, Tian M, Wickham LA, Lin J, Matheravidathu SS, Forrest MJ, Mandala S, Quackenbush EJ.

J Immunol. 2005 Dec 1;175(11):7151-61.

18.

Novel ketal ligands for the glucocorticoid receptor: in vitro and in vivo activity.

Smith CJ, Ali A, Balkovec JM, Graham DW, Hammond ML, Patel GF, Rouen GP, Smith SK, Tata JR, Einstein M, Ge L, Harris GS, Kelly TM, Mazur P, Thompson CM, Wang CF, Williamson JM, Miller DK, Pandit S, Santoro JC, Sitlani A, Yamin TT, O'Neill EA, Zaller DM, Carballo-Jane E, Forrest MJ, Luell S.

Bioorg Med Chem Lett. 2005 Jun 2;15(11):2926-31.

PMID:
15911283
19.

Novel heterocyclic glucocorticoids: in vitro profile and in vivo efficacy.

Thompson CF, Quraishi N, Ali A, Tata JR, Hammond ML, Balkovec JM, Einstein M, Ge L, Harris G, Kelly TM, Mazur P, Pandit S, Santoro J, Sitlani A, Wang C, Williamson J, Miller DK, Yamin TT, Thompson CM, O'Neill EA, Zaller D, Forrest MJ, Carballo-Jane E, Luell S.

Bioorg Med Chem Lett. 2005 Apr 15;15(8):2163-7.

PMID:
15808489
20.

Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.

Liu K, Xu L, Berger JP, Macnaul KL, Zhou G, Doebber TW, Forrest MJ, Moller DE, Jones AB.

J Med Chem. 2005 Apr 7;48(7):2262-5.

PMID:
15801817
21.

Novel N-arylpyrazolo[3,2-c]-based ligands for the glucocorticoid receptor: receptor binding and in vivo activity.

Ali A, Thompson CF, Balkovec JM, Graham DW, Hammond ML, Quraishi N, Tata JR, Einstein M, Ge L, Harris G, Kelly TM, Mazur P, Pandit S, Santoro J, Sitlani A, Wang C, Williamson J, Miller DK, Thompson CM, Zaller DM, Forrest MJ, Carballo-Jane E, Luell S.

J Med Chem. 2004 May 6;47(10):2441-52.

PMID:
15115388
22.

Skeletal muscle: a dual system to measure glucocorticoid-dependent transactivation and transrepression of gene regulation.

Carballo-Jane E, Pandit S, Santoro JC, Freund C, Luell S, Harris G, Forrest MJ, Sitlani A.

J Steroid Biochem Mol Biol. 2004 Feb;88(2):191-201.

PMID:
15084351
23.

Benzyl vinylogous amide substituted aryldihydropyridazinones and aryldimethylpyrazolones as potent and selective PDE3B inhibitors.

Edmondson SD, Mastracchio A, He J, Chung CC, Forrest MJ, Hofsess S, MacIntyre E, Metzger J, O'Connor N, Patel K, Tong X, Tota MR, Van der Ploeg LH, Varnerin JP, Fisher MH, Wyvratt MJ, Weber AE, Parmee ER.

Bioorg Med Chem Lett. 2003 Nov 17;13(22):3983-7.

PMID:
14592490
24.

O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.

Adams AD, Hu Z, von Langen D, Dadiz A, Elbrecht A, MacNaul KL, Berger JP, Zhou G, Doebber TW, Meurer R, Forrest MJ, Moller DE, Jones AB.

Bioorg Med Chem Lett. 2003 Oct 6;13(19):3185-90.

PMID:
12951090
25.

Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2.

Abbadie C, Lindia JA, Cumiskey AM, Peterson LB, Mudgett JS, Bayne EK, DeMartino JA, MacIntyre DE, Forrest MJ.

Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7947-52. Epub 2003 Jun 13.

26.
27.

Comparison of Cardiovascular Parameters and/or Serum Chemistry and Hematology Profiles in Conscious and Anesthetized Rhesus Monkeys (Macaca mulatta).

Hom GJ, Bach TJ, Carroll D, Forrest MJ, Mariano MA, Trainor CE, Wang PR, MacIntyre DE.

Contemp Top Lab Anim Sci. 1999 Mar;38(2):60-64.

PMID:
12086436
28.

Beta(3)-adrenoceptor agonist-induced increases in lipolysis, metabolic rate, facial flushing, and reflex tachycardia in anesthetized rhesus monkeys.

Hom GJ, Forrest MJ, Bach TJ, Brady E, Candelore MR, Cascieri MA, Fletcher DJ, Fisher MH, Iliff SA, Mathvink R, Metzger J, Pecore V, Saperstein R, Shih T, Weber AE, Wyvratt M, Zafian P, MacIntyre DE.

J Pharmacol Exp Ther. 2001 Apr;297(1):299-307.

PMID:
11259557
29.

Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4 -[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide.

Mathvink RJ, Tolman JS, Chitty D, Candelore MR, Cascieri MA, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Miller RR, Stearns RA, Tota L, Wyvratt MJ, Fisher MH, Weber AE.

J Med Chem. 2000 Oct 19;43(21):3832-6.

PMID:
11052788
30.

L-750355, a human beta3-adrenoceptor agonist; in vitro pharmacology and profile of activity in vivo in the rhesus monkey.

Forrest MJ, Hom G, Bach T, Candelore MR, Cascieri MA, Strader C, Tota L, Fisher MH, Szumiloski J, Ok HO, Weber AE, Wyvratt M, Vicario P, Marko O, Deng L, Cioffe C, Hegarty-Friscino B, MacIntyre E.

Eur J Pharmacol. 2000 Oct 27;407(1-2):175-81.

PMID:
11050305
31.

Human beta3-adrenergic receptor agonists containing 1,2,3-triazole-substituted benzenesulfonamides.

Brockunier LL, Parmee ER, Ok HO, Candelore MR, Cascieri MA, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Tota L, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 2000 Sep 18;10(18):2111-4.

PMID:
10999482
32.

Potent, selective 3-pyridylethanolamine beta3 adrenergic receptor agonists possessing a thiazole benzenesulfonamide pharmacophore.

Mathvink RJ, Tolman JS, Chitty D, Candelore MR, Cascieri MA, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Tota L, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 2000 Sep 4;10(17):1971-3.

PMID:
10987429
33.

Role of the melanocortin-4 receptor in metabolic rate and food intake in mice.

Chen AS, Metzger JM, Trumbauer ME, Guan XM, Yu H, Frazier EG, Marsh DJ, Forrest MJ, Gopal-Truter S, Fisher J, Camacho RE, Strack AM, Mellin TN, MacIntyre DE, Chen HY, Van der Ploeg LH.

Transgenic Res. 2000 Apr;9(2):145-54.

PMID:
10951699
34.

Substituted oxazole benzenesulfonamides as potent human beta3 adrenergic receptor agonists.

Ok HO, Reigle LB, Candelore MR, Cascieri MA, Colwell LF, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Strader CD, Tota L, Wang P, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 2000 Jul 17;10(14):1531-4.

PMID:
10915043
35.

Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective beta3 adrenergic receptor agonist antiobesity agents.

Biftu T, Feng DD, Liang GB, Kuo H, Qian X, Naylor EM, Colandrea VJ, Candelore MR, Cascieri MA, Colwell LF Jr, Forrest MJ, Hom GJ, MacIntyre DE, Stearns RA, Strader CD, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 2000 Jul 3;10(13):1431-4.

PMID:
10888325
36.

Discovery of an orally bioavailable alkyl oxadiazole beta3 adrenergic receptor agonist.

Feng DD, Biftu T, Candelore MR, Cascieri MA, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Miller RR, Stearns RA, Strader CD, Tota L, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 2000 Jul 3;10(13):1427-9.

PMID:
10888324
37.

Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.

Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I, et al.

J Pharmacol Exp Ther. 1999 Aug;290(2):551-60.

PMID:
10411562
38.

L-770,644: a potent and selective human beta3 adrenergic receptor agonist with improved oral bioavailability.

Shih TL, Candelore MR, Cascieri MA, Chiu SH, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Miller RR, Stearns RA, Strader CD, Tota L, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 1999 May 3;9(9):1251-4.

PMID:
10340609
39.

Human beta3 adrenergic receptor agonists containing imidazolidinone and imidazolone benzenesulfonamides.

Naylor EM, Parmee ER, Colandrea VJ, Perkins L, Brockunier L, Candelore MR, Cascieri MA, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Strader CD, Tota L, Wang PR, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 1999 Mar 8;9(5):755-8.

PMID:
10201842
40.

Human beta3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides.

Parmee ER, Naylor EM, Perkins L, Colandrea VJ, Ok HO, Candelore MR, Cascieri MA, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Miller RR, Stearns RA, Strader CD, Tota L, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 1999 Mar 8;9(5):749-54.

PMID:
10201841
42.

3-Pyridylethanolamines: potent and selective human beta 3 adrenergic receptor agonists.

Naylor EM, Colandrea VJ, Candelore MR, Cascieri MA, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Strader CD, Tota L, Wang PR, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 1998 Nov 3;8(21):3087-92.

PMID:
9873681
43.

3-Pyridyloxypropanolamine agonists of the beta 3 adrenergic receptor with improved pharmacokinetic properties.

Weber AE, Ok HO, Alvaro RF, Candelore MR, Cascieri MA, Chiu SH, Deng L, Forrest MJ, Hom GJ, Hutchins JE, Kao J, MacIntyre DE, Mathvink RJ, McLoughlin D, Miller RR, Newbold RC, Olah TV, Parmee ER, Perkins L, Stearns RA, Strader CD, Szumiloski J, Tang YS, Tota L, Fisher MH, et al.

Bioorg Med Chem Lett. 1998 Aug 18;8(16):2111-6.

PMID:
9873496
44.

Peroxisome proliferator-activated receptors gamma and alpha mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression.

Kelly LJ, Vicario PP, Thompson GM, Candelore MR, Doebber TW, Ventre J, Wu MS, Meurer R, Forrest MJ, Conner MW, Cascieri MA, Moller DE.

Endocrinology. 1998 Dec;139(12):4920-7.

PMID:
9832429
45.

A selective human beta3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys.

Fisher MH, Amend AM, Bach TJ, Barker JM, Brady EJ, Candelore MR, Carroll D, Cascieri MA, Chiu SH, Deng L, Forrest MJ, Hegarty-Friscino B, Guan XM, Hom GJ, Hutchins JE, Kelly LJ, Mathvink RJ, Metzger JM, Miller RR, Ok HO, Parmee ER, Saperstein R, Strader CD, Stearns RA, MacIntyre DE, et al.

J Clin Invest. 1998 Jun 1;101(11):2387-93.

46.

Attenuation of oxygen free radical formation and tissue injury during experimental inflammation by P-selectin blockade.

DeLano FA, Forrest MJ, Schmid-Schönbein GW.

Microcirculation. 1997 Sep;4(3):349-57.

PMID:
9329011
47.

Impairment of selectin-mediated leukocyte adhesion to venular endothelium in spontaneously hypertensive rats.

Suematsu M, Suzuki H, Tamatani T, Iigou Y, DeLano FA, Miyasaka M, Forrest MJ, Kannagi R, Zweifach BW, Ishimura Y, et al.

J Clin Invest. 1995 Oct;96(4):2009-16.

48.

Treatment of delayed-type hypersensitivity with inhibitors of the VLA-4 integrin.

Tamraz S, Arrhenius T, Chiem A, Forrest MJ, Gaeta FC, He YB, Lei J, Maewal A, Phillips ML, Vollger LW, et al.

Springer Semin Immunopathol. 1995;16(4):437-41. Review. No abstract available.

PMID:
7570294
49.

Modification of leukocyte adhesion in spontaneously hypertensive rats by adrenal corticosteroids.

Suzuki H, Zweifach BW, Forrest MJ, Schmid-Schönbein GW.

J Leukoc Biol. 1995 Jan;57(1):20-6.

PMID:
7530280
50.

Impaired leukocyte-endothelial cell interaction in spontaneously hypertensive rats.

Suzuki H, Schmid-Schönbein GW, Suematsu M, DeLano FA, Forrest MJ, Miyasaka M, Zweifach BW.

Hypertension. 1994 Dec;24(6):719-27.

PMID:
7995629

Supplemental Content

Loading ...
Support Center